Last reviewed · How we verify
Arterial embolus and thrombosis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Eliquis | apixaban | Bristol-Myers Squibb | Factor Xa inhibitor | Factor Xa (FXa) | 2012-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 1 drug in Arterial embolus and thrombosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Arterial embolus and thrombosis:
- Arterial embolus and thrombosis treatment updates — RSS
- Arterial embolus and thrombosis treatment updates — Atom
- Arterial embolus and thrombosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Arterial embolus and thrombosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/arterial-embolus-and-thrombosis. Accessed 2026-06-11.
Related
- Arterial embolus and thrombosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing